An investment of €13 million ($15.3 million) will create Europe’s largest site in Europe for biopharmaceuticals quality control services, says Clean Cells. Clean Biologics group subsidiary Clean Cells has begun constructing a facility set to quadruple its analysis and production capacity for biopharmaceuticals. The project has financial backing from healthcare investment fund ArchiMed, and the facility in Montaigu-Vendée, France is expected to be complete in September 2022, creating 80 new jobs in the region. “What motivated this expansion is the…

Sartorius has bolstered its virus clearance R&D capabilities in Lanarkshire, Scotland after signing a 15-year lease. The deal, of which financial details have not been disclosed, sees German life sciences firm Sartorius take over more than 8,500 square-feet within Maxim 3 at the Eurocentral park for various research. Lonza already has a presence in Glasgow, Scotland with a competence center for bioanalytics and a small team of experts for virus clearance services following its acquisition of BioOutsource in 2015. “This…

Lonza will invest in additional drug product manufacturing capabilities in Switzerland to accelerate existing service offerings in Basel and Visp. The expansion will see contract development manufacturing organization (CDMO) Lonza install an aseptic fill-finish line in Stein, Switzerland and expand drug product services in Basel and Visp. “We constantly assess our assets and invest in developing and installing new capacity and technology to meet the market demand in biologics,” Peter Droc, head of drug product services at Lonza told BioProcess…

Thermo Fisher will increase manufacturing capacity for fill-finish services at its Greenville, US facility with an $154 million investment.  Bioprocess vendor Thermo Fisher Scientific has unveiled plans to bolster its manufacturing capacity for sterile liquid and lyophilized filling, pre-filled syringes, and solid dose continuous manufacturing at its Greenville, North Carolina facility. The $154 million investment is not part of the firm’s recent $600 million CAPEX plan, which had the trade press salivating in March.  “Our continued growth in capabilities and capacity at our Greenville site has enabled us to support our clients’ needs and…

CDMO AGC Bio will expand its Heidelberg, Germany facility to increase its manufacturing capacities for customer pDNA and mRNA projects. The expansion, of which financial details have not been disclosed, sees contract development manufacturing organization (CDMO) AGC Biologics boost its current production capacity for plasmid-DNA (pDNA) and messenger RNA (mRNA) by adding an additional manufacturing line. The Heidelberg expansion will also include additional warehouse capacity, a cleanroom for mRNA development and production, and a process development lab for microbial protein…

With continued rollout and boosters on the horizon, Moderna has added space at CDMO Resilience’s Ontario, Canada site to its mRNA COVID-19 vaccine production network. No financial details have been divulged, but the multi-year deal will see contract development and manufacturing organization (CDMO) National Resilience produce mRNA for the Moderna COVID-19 vaccine at its facility in Mississauga, Ontario in Canada. Resilience added the 136,000 square-foot facility through the quiet acquisition of assets from Therapure Biopharma, and while Moderna told this publication it…